Genomic Health

What Genomic Health does

Genomic Health is a molecular diagnostics company that developed and commercialized the Oncotype DX portfolio of genomic-based diagnostic tests, addressing overtreatment and optimal treatment selection in early-stage cancer. Its core technology analyzes gene expression patterns in tumor tissue to generate recurrence risk and chemotherapy benefit scores, with the flagship Oncotype DX Breast Recurrence Score test analyzing early-stage HR+, HER2- breast cancer to predict adjuvant chemotherapy benefit. The portfolio was extended into ductal carcinoma in situ (Oncotype DX Breast DCIS Score) and colon cancer (Oncotype DX Colon Recurrence Score), and the franchise accumulated 22 years of clinical evidence anchored by landmark trials including TAILORx and RxPONDER, culminating in a Category 1A recommendation in NCCN Clinical Practice Guidelines and over 2 million patients tested globally.

The company's business model was a one-time per-test fee structure for genomic diagnostic testing services, sold through an enterprise field sales motion targeting healthcare providers and health systems. Oncotype DX tests were ordered by oncologists and performed in centralized laboratories, with reimbursement supported by guideline inclusion and evidence of approximately $10,000 in average lifetime healthcare savings per patient in the United States. Kim Popovits led the company as Chairman, CEO, and President, drawing on prior senior leadership experience at Genentech.

Genomic Health was acquired by Invitae for $4 billion, after which the Oncotype DX assets became part of Exact Sciences Corporation. Exact Sciences has subsequently been acquired by Abbott, integrating the Oncotype DX franchise into a broader global cancer diagnostics platform alongside products such as Cologuard, Oncodetect, and the Cancerguard multi-cancer early detection test.

Name

Genomic Health

Legal name

Genomic Health

Website

https://genomichealth.com

Company type

Private

Founded year

2000

Operating status

Acquired

Headcount range

501–1,000 employees

Short description

Genomic Health developed and commercialized the Oncotype DX portfolio of genomic diagnostic tests, guiding personalized cancer treatment decisions for breast, DCIS, and colon cancer patients. Acquired by Invitae for $4 billion; assets now under Abbott.

Ownership category

akta.pro rank

Product category

Molecular Cancer Diagnostics

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Breast Oncology (HLAKAFAJ), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Genomic diagnostic tests
• Cancer recurrence testing
• Molecular diagnostic assays
• Precision oncology testing
• Tumor genomic profiling

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Genomic diagnostic testing services: Genomic Health generates revenue through its proprietary Oncotype DX genomic tests that guide cancer treatment decisions. The tests are used by healthcare providers to determine appropriate treatment strategies for cancer patients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Genomic Health develops and commercializes genomic-based diagnostic tests, led by the Oncotype DX portfolio, which analyze gene expression in tumor tissue to predict cancer recurrence risk and chemotherapy benefit. The flagship Oncotype DX Breast Recurrence Score test guides adjuvant chemotherapy decisions for early-stage HR+, HER2- breast cancer, with related tests covering DCIS breast cancer and colon cancer. Tests are ordered by healthcare providers and performed in certified laboratories to support personalized oncology treatment planning.

Product overview

Genomic Health (acquired by Invitae) specializes in genomic-based diagnostic tests that guide cancer treatment decisions, particularly through the Oncotype DX portfolio. The Oncotype DX tests analyze the activity of genes in tumor tissue to generate scores that predict cancer recurrence risk and chemotherapy benefit, enabling personalized treatment planning for breast and colon cancer patients.

Differentiator

Problem solved

Functional benefit

Brands

• Oncotype DX Breast Recurrence Score: Genomic test that guides personalized treatment decisions for early-stage HR+, HER2- breast cancer. The only genomic assay proven to predict adjuvant chemotherapy benefit with Category 1A recommendation in NCCN Clinical Practice Guidelines. Has been used by over 2 million breast cancer patients worldwide.
• Oncotype DX Breast DCIS Score
• Oncotype DX Colon Recurrence Score

Products and services

• Oncotype DX Breast Recurrence Score Test A genomic test that analyzes gene expression patterns in tumor tissue to guide personalized adjuvant chemotherapy decisions for early-stage HR+, HER2- breast cancer patients, predicting chemotherapy benefit and recurrence risk. The only genomic assay proven to predict adjuvant chemotherapy benefit in breast cancer with Category 1A NCCN guideline endorsement, used by healthcare providers globally.
• Oncotype DX Breast DCIS Score Test A genomic assay for breast cancer that provides a recurrence risk score for patients with ductal carcinoma in situ (DCIS) to guide treatment decisions on adjuvant therapy, including radiation therapy planning.
• Oncotype DX Colon Recurrence Score Test A genomic test that analyzes tumor tissue to predict recurrence risk in stage II and stage III colon cancer patients, helping healthcare providers guide adjuvant chemotherapy treatment decisions.

Quantifiable outcome

• Over 2 million breast cancer patients tested worldwide
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Emerging players

• Guardant Health: Guardant Health is a leading liquid biopsy and oncology genomics company. While primarily focused on blood-based testing rather than tissue-based assays like Oncotype DX, it competes for oncology molecular testing budgets and physician mindshare.
• Natera: Natera provides cell-free DNA and molecular testing for oncology and reproductive health. Its Signatera MRD test competes in the broader oncology molecular testing market and for similar payer and provider relationships.
• Caris Life Sciences: Caris Life Sciences offers MI Profile and other molecular profiling tests for cancer treatment selection. It is an emerging competitor in tumor genomic profiling with overlapping oncologist and payer customers.

Broad incumbents

• Hologic: Hologic is a women's health diagnostics company whose mammography and breast cancer screening/diagnostic portfolio overlaps with the breast oncology segment Genomic Health serves.
• Foundation Medicine (Roche): Foundation Medicine, owned by Roche, provides comprehensive genomic profiling of solid tumors via FoundationOne. It is a broad incumbent in oncology molecular diagnostics competing for the same oncologist customers as Oncotype DX.
• Exact Sciences (now Abbott): Exact Sciences, now part of Abbott, owns the Oncotype DX franchise following its acquisition and is the direct parent of Genomic Health's products, also offering Cologuard and Oncodetect in adjacent oncology diagnostics categories.

Direct peers

• NeoGenomics: NeoGenomics provides oncology-focused clinical laboratory services including molecular and genetic testing for cancer, serving hospitals and oncologists with a portfolio that overlaps Genomic Health's tumor profiling work.
• Agendia: Agendia develops MammaPrint and BluePrint genomic tests for breast cancer recurrence risk and treatment guidance, directly competing with Oncotype DX in the adjuvant chemotherapy decision market for early-stage HR+/HER2- breast cancer.
• Myriad Genetics: Myriad Genetics offers molecular diagnostic tests including BRCA testing and oncology assays, competing in the broader hereditary and somatic cancer testing market that Genomic Health serves with Oncotype DX.
• Veracyte: Veracyte is a genomic diagnostics company focused on oncology, offering tests for thyroid, prostate, breast, and lung cancer, with overlapping product positioning and customer base (oncologists and pathologists) to Genomic Health.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/GenomicHealth
• Facebookfacebook.com/genomichealth
• LinkedInlinkedin.com/company/genomic-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genomic Health